Welcome to the EPA 2022 Interactive Programme 

The congress will officially run on Central European Summer Time (CEST/GMT +2) 

To convert the congress times to your local time Click Here 

Icon

Description automatically generatedFully Live with Live Q&A Icon

Description automatically generatedOn Demand (available from 4 June)  Icon

Description automatically generatedECP Session 

Icon

Description automatically generatedSection Session Icon

Description automatically generatedEPA Course (Pre-Registration Required)   Ask the Expert

Displaying One Session

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
13:00 - 13:45
Room
Industry session hall 2
Session Description
Treatment-resistant schizophrenia – What’s holding us back? -Supported by Viatris

Session Description:

Despite the existence of more than 60 antipsychotic therapeutic agents globally 20-30% of schizophrenia patients are resistant to treatment. There is a direct correlation between treatment initiation and improved clinical outcomes in treatment-resistant schizophrenia (TRS), thus defining treatment resistance in schizophrenia patients is utmost important, so that appropriate treatment can be administered as early as possible. Clozapine is the only evidence-based, effective, and approved treatment for TRS. Despite the evidence for its use, clozapine continues to be highly underutilized and initiated late. Failure to recognize TRS is an important clinical barrier to earlier initiation of clozapine. Clinicians should routinely, actively assess patients with schizophrenia for inadequate response to treatment. In his talk Professor Ofer Agid will review the clinical and biological aspects of treatment response and treatment resistance in first-episode schizophrenia, discuss an algorithm-based treatment approach and emphasize the importance of early positioning of clozapine to reduce the duration of active psychosis. Professor Swaran Singh in his lecture will talk about the barriers and list the various factors leading to clozapine’s underutilization and, in many cases, to its delayed initiation. He will also share practical advice and actions needed to overcome these barriers.

Session Icon
Fully Live

Introduction

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
13:00 - 13:45
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
13:00 - 13:03

Presentation Title: Treatment resistance in First Episode Schizophrenia – an algorithm based approach

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
13:00 - 13:45
Room
Industry session hall 2
Session Icon
Fully Live
Presenter
Lecture Time
13:03 - 13:20

Presentation Title: Overcoming clozapine initiation barriers

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
13:00 - 13:45
Room
Industry session hall 2
Session Icon
Fully Live
Presenter
Lecture Time
13:20 - 13:37

Q&A

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
13:00 - 13:45
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
13:37 - 13:42

Closing remarks

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
13:00 - 13:45
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
13:42 - 13:45